News
LENZ
8.40
-6.04%
-0.54
Lenz Therapeutics Earnings Call: High Spend, Growing Traction
TipRanks · 5h ago
LENZ Therapeutics: Q4 Results Highlight A Worrying Lack Of Market Demand (Rating Downgrade)
Seeking Alpha · 1d ago
Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week
The Motley Fool · 1d ago
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Simply Wall St · 1d ago
LENZ Therapeutics Price Target Cut to $26.00/Share From $52.00 by Citigroup
Dow Jones · 2d ago
LENZ Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 2d ago
Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $26
Benzinga · 2d ago
Lenz Therapeutics price target lowered to $26 from $52 at Citi
TipRanks · 2d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), LENZ Therapeutics (LENZ) and Sarepta Therapeutics (SRPT)
TipRanks · 3d ago
Buy Rating on VIZZ Underscored by Improving Prescription Trends and Long-Term Upside Despite Near-Term Revenue Revisions
TipRanks · 3d ago
LENZ Therapeutics Is Maintained at Buy by B of A Securities
Dow Jones · 3d ago
LENZ Therapeutics Price Target Cut to $29.00/Share From $35.00 by B of A Securities
Dow Jones · 3d ago
B of A Securities Maintains Buy on LENZ Therapeutics, Lowers Price Target to $29
Benzinga · 3d ago
Lenz Therapeutics price target lowered to $29 from $35 at BofA
TipRanks · 3d ago
LENZ THERAPEUTICS INC <LENZ.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $20 FROM $36
Reuters · 3d ago
LENZ THERAPEUTICS INC <LENZ.O>: BOFA GLOBAL RESEARCH CUTS PRICE OBJECTIVE TO $29 FROM $35
Reuters · 3d ago
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and LENZ Therapeutics (LENZ)
TipRanks · 3d ago
U.S. RESEARCH ROUNDUP-Amazon, Diamondback Energy, Matador Resources
Reuters · 3d ago
LENZ THERAPEUTICS INC <LENZ.O>: PIPER SANDLER CUTS TARGET PRICE TO $39 FROM $62
Reuters · 4d ago
LENZ Therapeutics (LENZ) Loss Deepens As VIZZ Launch Tests Bullish Growth Narratives
Simply Wall St · 4d ago
More
Webull provides a variety of real-time LENZ stock news. You can receive the latest news about LENZ THERAPEUTICS INC through multiple platforms. This information may help you make smarter investment decisions.
About LENZ
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.